Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Active, not recruiting · NCT03319940 · Registry updated 2025-11-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | Bites and Stings, Chemically-Induced Disorders, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, injury, lung disorder, lung neoplasm, neoplasm, poisoning, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 1 | 2025-11-19 | NCT03319940 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
39 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.